Q-omics provides the consensus-scored GOLT1A profile across patient tissues and cancer cell-line models. GOLT1A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GOLT1A is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, GOLT1A RNA expression shows 15,565 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, THCA, and TGCT as cancer lineages where GOLT1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLT1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLT1A survival associations across molecular data types. GOLT1A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLT1A RNA expression–survival associations across cancer types. High GOLT1A expression shows unfavorable associations in KIRP, UVM, LUSC and COAD, but favorable associations in ACC and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GOLT1A RNA expression.
This table summarizes GOLT1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GOLT1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLT1A shows lower tumor expression in LUSC and higher tumor expression in THCA, COAD, BRCA, STAD and UCEC. The THCA box plot shows higher GOLT1A RNA expression in tumor versus normal tissue (log2 FC = +3.755, t-test p < 0.001).
This table shows molecular features associated with GOLT1A in patient tissues and cancer cell lines. In patient samples, GOLT1A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLT1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
